Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells

Virology

Volumn 376, Issue 1, 2008, Pages 101-111

  Kijak, Gustavo H ^a   Janini, Luiz Mario ^a,b   Tovanabutra, Sodsai ^a   Sanders Buell, Eric ^a   Arroyo, Miguel Angel ^a,c   Robb, Merlin L ^a   Michael, Nelson L ^c   Birx, Debora L ^c   McCutchan, Francine E ^a  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

APOBEC3F; APOBEC3G; HIV 1; Host restriction; Hypermutation; Innate immunity

Indexed keywords

VIF PROTEIN;

ARTICLE; CPG ISLAND; DEAMINATION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PRIORITY JOURNAL; PROVIRUS;

BLOOD; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; MUTATION; PROVIRUSES; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 43849109664     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.03.017     Document Type: Article

References (67)

1. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Vlahov D., Donfield S., Goedert J.J., Phair J., Buchbinder S., O'Brien S.J., Telenti A., and Winkler C.A. APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 78 20 (2004) 11070-11076
2. Arroyo M.A., Hoelscher M., Sanders-Buell E., Herbinger K.H., Samky E., Maboko L., Hoffmann O., Robb M.R., Birx D.L., and McCutchan F.E. HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res. Hum. Retrovir. 20 8 (2004) 895-901
3. Arroyo M.A., Hoelscher M., Sateren W., Samky E., Maboko L., Hoffmann O., Kijak G., Robb M., Birx D.L., and McCutchan F.E. HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. Aids 19 14 (2005) 1517-1524
4. Beale R.C., Petersen-Mahrt S.K., Watt I.N., Harris R.S., Rada C., and Neuberger M.S. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337 3 (2004) 585-596
5. Berkhout B., and van Hemert F.J. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res. 22 9 (1994) 1705-1711
6. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 15 (2004) 1392-1396
7. Braaten D., and Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 20 6 (2001) 1300-1309
8. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., Nguyen P.L., Khoruts A., Larson M., Haase A.T., and Douek D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200 6 (2004) 749-759
9. Carr J.K., Laukkanen T., Salminen M.O., Albert J., Alaeus A., Kim B., Sanders-Buell E., Birx D.L., and McCutchan F.E. Characterization of subtype A HIV-1 from Africa by full genome sequencing. Aids 13 14 (1999) 1819-1826
10. Chelico L., Pham P., Calabrese P., and Goodman M.F. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 13 5 (2006) 392-399
11. Chiu Y.L., Soros V.B., Kreisberg J.F., Stopak K., Yonemoto W., and Greene W.C. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435 7038 (2005) 108-114
12. Coker H.A., and Petersen-Mahrt S.K. The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. DNA Repair (Amst.) 6 2 (2007) 235-243
13. Connor R.I., Sheridan K.E., Ceradini D., Choe S., and Landau N.R. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185 4 (1997) 621-628
14. Cooper G.M. The Cell, a Molecular Approach (2000), ASM Press
15. Diamond T.L., Kimata J., and Kim B. Identification of a simian immunodeficiency virus reverse transcriptase variant with enhanced replicational fidelity in the late stage of viral infection. J. Biol. Chem. 276 26 (2001) 23624-23631
16. Do H., Vasilescu A., Diop G., Hirtzig T., Heath S.C., Coulonges C., Rappaport J., Therwath A., Lathrop M., Matsuda F., and Zagury J.F. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J. Infect. Dis. 191 2 (2005) 159-163
17. Dowling W.E., Kim B., Mason C.J., Wasunna K.M., Alam U., Elson L., Birx D.L., Robb M.L., McCutchan F.E., and Carr J.K. Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. Aids 16 13 (2002) 1809-1820
18. Fitzgibbon J.E., Mazar S., and Dubin D.T. A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retrovir. 9 9 (1993) 833-838
19. Goff S.P. Retrovirus restriction factors. Mol. Cell 16 6 (2004) 849-859
20. Gonzalez E., Kulkarni H., Bolivar H., Mangano A., Sanchez R., Catano G., Nibbs R.J., Freedman B.I., Quinones M.P., Bamshad M.J., Murthy K.K., Rovin B.H., Bradley W., Clark R.A., Anderson S.A., O'Connell R.J., Agan B.K., Ahuja S.S., Bologna R., Sen L., Dolan M.J., and Ahuja S.K. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 5714 (2005) 1434-1440
21. Graziosi C., Soudeyns H., Rizzardi G.P., Bart P.A., Chapuis A., and Pantaleo G. Immunopathogenesis of HIV infection. AIDS Res. Hum. Retrovir. 14 Suppl 2 (1998) S135-S142
22. Harris M.E., Serwadda D., Sewankambo N., Kim B., Kigozi G., Kiwanuka N., Phillips J.B., Wabwire F., Meehen M., Lutalo T., Lane J.R., Merling R., Gray R., Wawer M., Birx D.L., Robb M.L., and McCutchan F.E. Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res. Hum. Retrovir. 18 17 (2002) 1281-1290
23. Harris M.E., Maayan S., Kim B., Zeira M., Ferrari G., Birx D.L., and McCutchan F.E. A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. AIDS Res. Hum. Retrovir. 19 12 (2003) 1125-1133
24. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev., Immunol. 4 11 (2004) 868-877
25. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., and Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35 21 (2007) 7096-7108
26. Janini M., Carr J., Birx D., and McCutchan F. AIDS Vaccine (2001), Philadelphia, PA, USA
27. Janini M., Rogers M., Birx D.R., and McCutchan F.E. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol. 75 17 (2001) 7973-7986
28. Jin X., Brooks A., Chen H., Bennett R., Reichman R., and Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79 17 (2005) 11513-11516
29. Jin X., Wu H., and Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 4 (2007) 20
30. Kijak G.H., Janini M., Tovanabutra S., Sanders-Buell E.E., Birx D.L., Robb M.L., Michael N.L., and McCutchan F.E. HyperPack: a software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV. AIDS Res. Hum. Retrovir. 23 4 (2007) 554-557
31. Kreisberg J.F., Yonemoto W., and Greene W.C. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203 4 (2006) 865-870
32. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 5622 (2003) 1112
33. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 15 (2004) 1385-1391
34. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., and Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 3 (1996) 367-377
35. Li X.Y., Guo F., Zhang L., Kleiman L., and Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282 44 (2007) 32065-32074
36. Martinez M.A., Vartanian J.P., and Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. U. S. A. 91 25 (1994) 11787-11791
37. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., and Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200 6 (2004) 761-770
38. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 9 (2004) 7792-7798
39. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., and Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of HIV-1. J. Virol. 81 24 (2007) 13346-13353
40. Overbaugh J., Jackson S.M., Papenhausen M.D., and Rudensey L.M. Lentiviral genomes with G-to-A hypermutation may result from Taq polymerase errors during polymerase chain reaction. AIDS Res. Hum. Retrovir. 12 17 (1996) 1605-1613
41. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., and Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80 18 (2006) 9259-9269
42. Pathak V.K., and Temin H.M. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc. Natl. Acad. Sci. U. S. A. 87 16 (1990) 6019-6023
43. Peng G., Lei K.J., Jin W., Greenwell-Wild T., and Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203 1 (2006) 41-46
44. Rose K.M., Marin M., Kozak S.L., and Kabat D. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res. Hum. Retrovir. 21 7 (2005) 611-619
45. Salminen M.O., Carr J.K., Burke D.S., and McCutchan F.E. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res. Hum. Retrovir. 11 11 (1995) 1423-1425
46. Salminen M.O., Koch C., Sanders-Buell E., Ehrenberg P.K., Michael N.L., Carr J.K., Burke D.S., and McCutchan F.E. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology 213 1 (1995) 80-86
47. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 6593 (1996) 722-725
48. Sarkis P.T., Ying S., Xu R., and Yu X.F. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177 7 (2006) 4530-4540
49. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 6898 (2002) 646-650
50. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., and Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1 1 (2005) e6
51. Soros V.B., Yonemoto W., and Greene W.C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3 2 (2007) e15
52. Stopak K.S., Chiu Y.L., Kropp J., Grant R.M., and Greene W.C. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282 6 (2007) 3539-3546
53. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 6977 (2004) 848-853
54. Suspene R., Sommer P., Henry M., Ferris S., Guetard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., and Vartanian J.P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32 8 (2004) 2421-2429
55. Suspene R., Rusniok C., Vartanian J.P., and Wain-Hobson S. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34 17 (2006) 4677-4684
56. Tovanabutra S., Beyrer C., Sakkhachornphop S., Razak M.H., Ramos G.L., Vongchak T., Rungruengthanakit K., Saokhieo P., Tejafong K., Kim B., De Souza M., Robb M.L., Birx D.L., Jittiwutikarn J., Suriyanon V., Celentano D.D., and McCutchan F.E. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res. Hum. Retrovir. 20 5 (2004) 465-475
57. Tovanabutra S., Brodine S.K., Mascola J.R., Sankale J.L., Sanders-Buell E., Kim B., Birx D.L., and McCutchan F.E. Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. AIDS Res. Hum. Retrovir. 21 5 (2005) 424-429
58. Valcke H.S., Bernard N.F., Bruneau J., Alary M., Tsoukas C.M., and Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. Aids 20 15 (2006) 1984-1986
59. Vartanian J.P., Meyerhans A., Asjo B., and Wain-Hobson S. Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65 4 (1991) 1779-1788
60. Vartanian J.P., Meyerhans A., Sala M., and Wain-Hobson S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 91 8 (1994) 3092-3096
61. Wang T., Tian C., Zhang W., Luo K., Thi P., Sarkis N., Yu L., Liu B., Yu Y., and Yu X.F. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81 23 (2007) 13112-13124
62. Wang X., Dolan P.T., Dang Y., and Zheng Y.H. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J. Biol. Chem. 282 3 (2007) 1585-1594
63. Watanaveeradej V., Benenson M.W., Souza M.D., Sirisopana N., Nitayaphan S., Tontichaivanich C., Amphaipit R., Renzullo P.O., Brown A.E., McNeil J.G., Robb M.L., Birx D.L., Tovanabutra S., Carr J.K., and McCutchan F.E. Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping. AIDS Res. Hum. Retrovir. 22 8 (2006) 801-807
64. Xu H., Chertova E., Chen J., Ott D.E., Roser J.D., Hu W.S., and Pathak V.K. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360 2 (2007) 247-256
65. Ying S., Zhang X., Sarkis P.T., Xu R., and Yu X. Cell-specific regulation of APOBEC3F by interferons. Acta Biochim. Biophys. Sin. (Shanghai) 39 4 (2007) 297-304
66. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., and Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 5 (2004) 435-442
67. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 11 (2004) 6073-6076